

**Fiscal Year 2026 Congressionally Directed Medical Research Programs  
Peer Reviewed Medical Research Program (PRMRP)  
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Trial Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> HT942526PRMRPCTA</p>	<p>Independent investigators at all career levels.</p>	<ul style="list-style-type: none"> <li>• Supports the rapid execution and analysis of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition addressed in one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals.</li> <li>• Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.</li> <li>• Applications <b>cannot</b> support preclinical research.</li> <li>• <b>Preproposal submission is required; application submission is by invitation only.</b></li> <li>• <b>Clinical Trial Only Option: Applications must include documentation demonstrating U.S. Food and Drug Administration (FDA) or other regulatory approval or exemption to proceed, as applicable.</b></li> <li>• <b>Clinical Trial with Planning Phase Option:</b> The Planning Phase provides support to prepare and submit an Investigational New Drug or Investigational Device Exemption application to the FDA. <b>Requires</b> FDA or other regulatory approval or exemption to proceed before commencing the clinical trial option.</li> <li>• <b>Funding Levels:</b> Three funding levels are offered with or without a Planning Phase; each funding level describes a defined clinical trial scope: <ul style="list-style-type: none"> <li>○ <b>Funding Level 1:</b> Provides support for a phase 0 or phase 1 clinical trial or non-phased trial with fewer than 100 subjects.</li> <li>○ <b>Funding Level 2:</b> Provides support for a phase 2 clinical trial or non-phased trial with fewer than 300 subjects.</li> <li>○ <b>Funding Level 3:</b> Provides support for a phase 3 clinical trial or non-phased trials with greater than 300 subjects.</li> </ul> </li> </ul>	<p><b>Clinical Trial with Planning Phase – All Funding Levels:</b></p> <ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$800,000</b> for total costs for <b>Planning Phase</b>.*</li> <li>• The maximum period of performance is <b>12</b> months.</li> </ul> <p><b>All Funding Levels:</b></p> <ul style="list-style-type: none"> <li>• The maximum period of performance is <b>4</b> years.</li> </ul> <p><b>Funding Level 1:</b></p> <ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$6.0 million (M)</b> for total costs.*</li> </ul> <p><b>Funding Level 2:</b></p> <ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$10.0M</b> for total costs.*</li> </ul> <p><b>Funding Level 3:</b></p> <ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$20.0M</b> for total costs.*</li> </ul>	<p><b>Pre-Application (Preproposal):</b> July 23, 2026 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 22, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Discovery Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942526PRMRPDA</p>	<p>Investigators at all career levels.</p>	<ul style="list-style-type: none"> <li>Supports innovative, untested, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications with impact on one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals.</li> <li>Applications cannot support the logical progression of an already established line of questioning.</li> <li>Applications <b>must not</b> include preliminary data.</li> <li><b>Clinical trials are not allowed.</b></li> <li><b>Submission of a letter of intent is required prior to full application submission.</b></li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$385,000</b> for total costs.*</li> <li>The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b></p> <p>July 16, 2026 5:00 p.m. Eastern time</p> <p><b>Application:</b></p> <p>July 30, 2026 11:59 p.m. Eastern time</p>
<p><b>Impact Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942526PRMRPIPA</p>	<p>Independent investigators at all career levels.</p>	<ul style="list-style-type: none"> <li>Supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research and insights from the real-world environment to foster clinical applicability.</li> <li>Applications should demonstrate the potential to make a near-term, major impact on one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals.</li> <li><b>Partnering Principal Investigator (PI) Option:</b> Supports meaningful and productive partnerships between two investigators, termed the initiating PI and partnering PI, collaborating on a single application. At least one PI must be a clinician researcher.</li> <li><b>Clinical trials are not allowed.</b></li> <li><b>Submission of a letter of intent is required prior to full application submission.</b></li> </ul>	<p><b>Single PI Option:</b></p> <ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$2.8M</b> for total costs.*</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul> <p><b>Partnering PI Option:</b></p> <ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$3.6M</b> for total costs.*</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b></p> <p>July 23, 2026 5:00 p.m. Eastern time</p> <p><b>Application:</b></p> <p>August 6, 2026 11:59 p.m. Eastern time</p>
<p><b>Lifestyle and Applied Health Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942526PRMRPLAHRA</p>	<p>Independent investigators at all career levels.</p>	<ul style="list-style-type: none"> <li>Supports clinical research and/or clinical trials using a combination of scientific disciplines, including occupational science, psychology, psychometrics, biostatistics and epidemiology, surveillance, implementation science, and population health.</li> <li>Applications must address and provide a solution to one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals.</li> <li>Proposed projects may target the development of evidence-based practices, applied health science interventions, and the investigation of psychosocial patient outcomes.</li> <li>Applications <b>cannot</b> support animal studies.</li> <li><b>Submission of a letter of intent is required prior to full application submission.</b></li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$4.2M</b> for total costs.*</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b></p> <p>July 23, 2026 5:00 p.m. Eastern time</p> <p><b>Application:</b></p> <p>August 6, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Platform Clinical Translation Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> HT942526PRMRPPCTA</p>	<p>Independent investigators at all career levels.</p>	<ul style="list-style-type: none"> <li>• Supports the translational development and/or early-phase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to <b>two FY26 PRMRP topic areas</b>.</li> <li>• Applications must address one of the FY26 PRMRP strategic goals.</li> <li>• <b>Partnering PI Option:</b> Supports meaningful and productive partnerships between investigators, termed the initiating PI and partnering PI(s), collaborating on a single application. Applications allow up to two partnering PIs.</li> <li>• <b>Preproposal submission is required; application submission is by invitation only.</b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$15.0M</b> for total costs.* <ul style="list-style-type: none"> <li>◦ Only <b>\$8.0M</b> is currently available with FY26 funds; additional costs supported as optional research efforts.</li> </ul> </li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> July 23, 2026 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 22, 2026 11:59 p.m. Eastern time</p>
<p><b>Research Advancement Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> HT942526PRMRPRAA</p>	<p>Independent investigators at all career levels.</p>	<ul style="list-style-type: none"> <li>• Supports fundamental research studies that will make an important contribution towards research, patient care, and/or quality of life for a disease or condition related to one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals.</li> <li>• <b>Clinical trials are not allowed.</b></li> <li>• <b>Submission of a letter of intent is required prior to full application submission.</b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$1.4M</b> for total costs.*</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 16, 2026 5:00 p.m. Eastern time</p> <p><b>Application:</b> July 30, 2026 11:59 p.m. Eastern time</p>
<p><b>Technology/Therapeutic Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> HT942526PRMRPTTDA</p>	<p>Independent investigators at all career levels.</p>	<ul style="list-style-type: none"> <li>• Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals.</li> <li>• Applications <b>must</b> describe product-oriented research. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision-making tools or practice guidelines.</li> <li>• Applications must include preliminary data demonstrating proof-of-concept for the product.</li> <li>• <b>Clinical trials are not allowed.</b></li> <li>• <b>Submission of a letter of intent is required prior to full application submission.</b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$5.6M</b> for total costs.*</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 23, 2026 5:00 p.m. Eastern time</p> <p><b>Application:</b> August 6, 2026 11:59 p.m. Eastern time</p>

\*Total costs include direct and indirect costs.